AI Tool Comparison
Comparing as AI Medical Research & Clinical Decision SupportSchrödinger vs BenevolentAI
Schrödinger
VS
BenevolentAI
Verdict by Category
Detailed Comparison
Feature
Schrödinger
BenevolentAI
Pricing
PaidSchrödinger offers software through subscription licenses and hosted cloud access.
Enterprise pharma customers access the full suite (Maestro, Glide, FEP+, Jaguar, Prime, and Bunsen AI) through annual software licensing agreements. Pricing is tiered by organization size, usage volume, and modules required. Enterprise software ACV reached $198.5M in 2025.
Academic and government institutions access Schrödinger tools through educational licensing at significantly reduced rates. Cloud-hosted subscriptions are also available for teams preferring managed infrastructure.
Drug discovery partnerships with pharma (BMS, Sanofi, Takeda) are structured as sponsored research and co-development agreements with milestone-based payments. Contact Schrödinger through schrodinger.com for enterprise pricing, academic licenses, or partnership inquiries.
CustomBenevolentAI operates through enterprise pharma collaboration agreements and platform licensing — there is no self-serve access or published pricing.
Revenue models include: discovery collaborations with pharma companies (AstraZeneca, Merck) structured as multi-year agreements with upfront fees and milestones; licensing of its knowledge exploration tools as standalone software to pharma R&D organizations; and advancing its own clinical pipeline to inflection points for licensing or co-development.
Total funding raised is approximately $1.9B, with the company listed on Euronext Amsterdam (AMS: BAI). Contact BenevolentAI through benevolent.com for partnership and platform licensing inquiries.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
Physics-based drug discovery with Bunsen AI co-scientist — trusted by 500+ pharma companies worldwide
Clinical-stage AI drug discovery with integrated wet labs and AstraZeneca and Merck collaborations
Schrödinger Pros & Cons
Pros
- 34+ years of computational chemistry leadership — most trusted physics-based platform in pharma
- Bunsen AI co-scientist launched July 2026 — BMS immediately deployed it
- FEP+ delivers industry-leading accuracy in binding affinity prediction
- NASDAQ SDGR — $255.87M revenue in 2025, 23% growth, turning profitable in Q2 2026
- 500+ pharma enterprise customers including BMS, Sanofi, Takeda, Pfizer, and Eli Lilly
- Materials science applications extend reach to battery, semiconductor, and chemical sectors
- Cloud-hosted subscriptions eliminate on-premise infrastructure burden
Cons
- Software is expensive — enterprise pricing puts it out of reach for smaller labs
- Stock (SDGR) has been under pressure — market cap ~$1B despite strong platform
- Drug discovery segment revenue is milestone-dependent and lumpy
- Platform learning curve is steep without computational chemistry background
- Competition from newer, purely AI-native platforms is intensifying
BenevolentAI Pros & Cons
Pros
- Fully integrated AI + wet lab model — unique among AI drug discovery platforms
- AstraZeneca and Merck partnerships validate the platform's target identification quality
- In-house wet labs in Cambridge close the loop between AI prediction and biology
- Euronext Amsterdam listed (AMS: BAI) — $1.9B raised, publicly accountable
- Phase 1 clinical data for BEN-8744 (ulcerative colitis) represents real clinical progress
- Multiple disease areas covered: oncology, rare disease, CNS, fibrosis, and immunology
- Knowledge exploration tools can be licensed separately from drug pipeline
Cons
- Listed on Euronext Amsterdam (AMS: BAI) — less accessible to US retail investors
- Clinical pipeline still in early stages — no approved drugs yet
- Smaller than competitors like Recursion in terms of funding and team size
- Revenue dependent on collaboration milestones — lumpy and uncertain
- Wet-lab operations add cost complexity vs. pure software drug discovery peers